| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18752 R79756 |
Moore (Gabapentin) (Mixed indications) (Controls exposed to LTG), 2025 | Early childhood developmental concerns (any developmental concerns on any domain at the 27–30 month assessment offered to all children) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.26 [1.03;1.54] C excluded (control group) |
308/1,128 215/934 | 523 | 1,128 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18753 R79760 |
Moore (Gabapentin) (Mixed indications) (Controls unexposed, general pop), 2025 | Early childhood developmental concerns (any developmental concerns on any domain at the 27–30 month assessment offered to all children) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Matched | 1.19 [1.02;1.39] | 308/1,128 1,755/11,276 | 2,063 | 1,128 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12760 R48138 |
Bjørk (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 - Median follow up gabapentin 3.5 (1.7-6.7) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.74 [0.41;1.34] C excluded (control group) |
12/965 133/7,950 | 145 | 965 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12761 R48140 |
Bjørk (Controls unexposed NOS) (Mixed indications), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 - Median follow up gabapentin 3.5 (1.7-6.7) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
0.96 [0.54;1.69] excluded (control group) |
12/965 68,295/4,463,879 | 68,307 | 965 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12762 R48142 |
Bjørk (Controls unexposed, sick) (Mixed indications), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 - Median follow up gabapentin 3.5 (1.7-6.7) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication | 0.60 [0.34;1.07] C | 12/965 443/21,634 | 455 | 965 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8517 R28095 |
Coste (Controls unexposed, NOS) (Mixed indications), 2020 | Diagnosis Disorders of psychological development (F80–F89) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.30 [0.50;3.30] | 4/378 10,010/1,710,441 | 10,014 | 378 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8485 R27856 |
Arkilo, 2015 | Abnormal development (At 2 years of age, assessed by developmental specialists) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 8.60 [0.14;536.34] C | 0/1 2/24 | 2 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8486 R27860 |
Dean, 2002 | Developmental delay | at least 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 7.44 [0.13;423.73] C | 0/1 4/38 | 4 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 1.04 [0.66;1.62] | 12,538 | 2,473 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Gabapentin) (Mixed indications) (Controls unexposed, general pop; 2: Controls unexposed, sick) (Mixed indications; 3: Controls unexposed, NOS) (Mixed indications;
Asymetry test p-value = 0.8831 (by Egger's regression)
slope=0.1215 (0.1472); intercept=0.1400 (0.8753); t=0.1600; p=0.8831
excluded 12760, 12761, 18752